Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD1 | P21728 | 3/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191819 | 0.91 | ADRB2 (0.43) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3843719 | 0.91 | ADRB2 (0.63) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3176079 | 0.88 | ADRB2 (0.42) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3196487 | 0.87 | ADRB2 (0.66) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL17979457 | 0.85 | ADRB2 (0.49) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL17979458 | 0.85 | ADRB2 (0.49) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL962871 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL13708455 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL776543 | 0.84 | ADRB2 (0.45) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL14417635 | 0.84 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662815-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-05-15 | — | — | US | disclosed |
| US-7317023-B2 | Diaryl ether β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019991-A1 | Diaryl ether beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 5/4885 |
| US-20080113981-A1 | Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.